<DOC>
	<DOCNO>NCT00035490</DOCNO>
	<brief_summary>Implantable cardioverter defibrillator ( ICDs ) develop treat ventricular tachycardia fibrillation ( abnormal heart rhythm ) electrical shock pace heart . ICD therapy establish highly effective stop life-threatening arrhythmia , preclude use anti-arrhythmic drug prevention decrease frequency ICD shock . The safety effectiveness oral azimilide dihydrochloride reduce frequency ICD shock investigate previously placebo-controlled study patient ICDs . These result need confirmed large double-blind , placebo-controlled study approximately 600 patient .</brief_summary>
	<brief_title>Efficacy Safety Evaluation Azimilide Dihydrochloride Patients With Implantable Cardioverter Defibrillators</brief_title>
	<detailed_description />
	<mesh_term>Azimilide</mesh_term>
	<criteria>Inclusion criterion : Currently ICD implant Have document episode symptomatic arrhythmia trigger spontaneous ICD shock within 180 day randomization . If ICD implant recent , patient must document episode sustain arrhythmias cardiac arrest within 42 day implantation ICD Exclusion criterion : severe heart failure current diagnosis psychosis use illicit drug abuse alcohol female , currently breast feeding , plan become pregnant study currently take antiarrhythmic drug drug prolong QTc interval ( measurement take ECG ) creatinine &gt; 2.5 mg/dL ( 221 mmol/L ) potassium &lt; 4.0 mEq &gt; 5.5 mEq neutrophil count ( ANC ) &lt; 100 mL ( low count type white blood cell ) time randomization 2 consecutive QTc value &gt; 440 msec</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>